Gastroenterology January 2026Selective Urokinase Inhibition Plus Chemotherapy: A Novel Approach to Pancreatic Cancer Treatment via Enhanced Antitumor Immunity and Decreased Metastasis

Researchers have developed a promising new strategy to combat pancreatic cancer by using a specialized inhibitor called BB2–30F to block the uPA enzyme system, which typically drives tumor spread. By combining this inhibitor with traditional chemotherapy, the study demonstrated a significant ability to stunt primary tumor growth and, remarkably, eliminate visible distant metastasis in animal models. The treatment works by disrupting the harmful dialogue between cancer cells and their surroundings, effectively reprogramming the immune system to attack the tumor more aggressively. Ultimately, this approach offers a sophisticated blueprint for improving patient survival by targeting the specific biological pathways that make this particular cancer so deadly and resilient.